Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUBLOCADE Bioavailability at Alternative Injection Sites
NCT05704543Phase 4Completed
- Sponsor
- Indivior
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of buprenorphine extended-release injection in opioid use disorder (OUD), sponsored by Indivior. Started Mar 2023; status: completed.
02
Drugs
buprenorphine extended-release injection
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05704543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704543.